Why insider trading matters?

What separates FormWhispers.com from others is that we created it to meet our own needs and we use it everyday to make better investment decisions. We will keep improving it to serve us better and to serve you better.

- Founders of FormWhispers.com
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.